Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON)

D. Stempel, L. Sutton, A. Emmett, P. Dorinsky (Bellevue, Raleigh, United States Of America)

Source: Annual Congress 2003 - Asthma in primary care
Session: Asthma in primary care
Session type: Thematic Poster Session
Number: 1702
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Stempel, L. Sutton, A. Emmett, P. Dorinsky (Bellevue, Raleigh, United States Of America). Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON). Eur Respir J 2003; 22: Suppl. 45, 1702

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 236s
Year: 2003

Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 44s
Year: 2004

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects.
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019



Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Lower ICS dose effect on symptoms and rescue medication use of  indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020


Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 457s
Year: 2007

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005